X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BT524 is a fibrinogen concentrate which acts as as fibrinogen stimulant. It is being developed for the treatment of acquired fibrinogen deficiency (AFD).
Lead Product(s): BT524
Therapeutic Area: Hematology Product Name: BT524
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
PROLASTIN®-C is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI.
Lead Product(s): Human Alpha1-Proteinase Inhibitor
Therapeutic Area: Genetic Disease Product Name: Prolastin-C
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
Albutein® (albumin-human injection) is an abundant protein in plasma which has antioxidant and anti-inflammatory properties, and is being investigated for the treatment of decompensated Cirrhosis.
Lead Product(s): Human Albumin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Albutein
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
PROLASTIN®-C is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI.
Lead Product(s): Human Alpha1-Proteinase Inhibitor
Therapeutic Area: Genetic Disease Product Name: Prolastin-C
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
PROLASTIN®-C is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI.
Lead Product(s): Human Alpha1-Proteinase Inhibitor
Therapeutic Area: Genetic Disease Product Name: Prolastin-C
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
Grifols will develop and commercialise immunoglobulin eye drops, SLG-100, for dry eye disease. An immunoglobulin eye drop is a biologic drug that contains naturally occurring functional antibodies generated from human plasma collected from thousands of healthy donors.
Lead Product(s): SLG-100
Therapeutic Area: Ophthalmology Product Name: SLG-100
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Selagine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2023
Details:
As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of Antithrombin III (AT-III), a plasma protein that treats patients with blood clotting issues.
Lead Product(s): Antithrombin III
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-III
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Endpoint Health
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 24, 2022
Details:
VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending.
Lead Product(s): VCN-01,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: VCN Biosciences
Deal Size: $77.4 million Upfront Cash: $4.7 million
Deal Type: Acquisition December 14, 2021
Details:
This acquisition will significantly reinforce Grifols’ industry capabilities by enhancing its plasmaderived medicines access, pipeline Biotest is leading clinical trials on plasma-derived fibrinogen (BT524) to treat congenital and acquired disorders.
Lead Product(s): BT524
Therapeutic Area: Genetic Disease Product Name: BT524
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Tianjin Tiancheng Pharma. Co., Ltd.
Deal Size: $1,281.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 17, 2021
Details:
GIGA-2050 is comprised of more than 12,000 antibodies demonstrating strong neutralizing activity against natural SARS CoV-2 variants in laboratory studies, including the delta variant and other variants that have emerged globally since the beginning of the pandemic.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
